Brief: Pharmather Provides Update Of Its Priority Original Abbreviated New Drug Application For Ketamine
18/04/2024 21:19
April 18 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER PROVIDES UPDATE OF ITS PRIORITY ORIGINAL
ABBREVIATED
NEW DRUG APPLICATION FOR KETAMINE
* PHARMATHER HOLDINGS LTD: HAS COMPLETED NECESSARY TESTS AND
RESPONSES TO ADDRESS FDA'S COMMENTS
* PHARMATHER HOLDINGS LTD - RECEIPT OF A COMPLETE RESPONSE
LETTER
("CRL") FOR ITS PRIORITY ORIGINAL ABBREVIATED NEW DRUG
APPLICATION FOR KETAMINE
* PHARMATHER PROVIDES UPDATE OF ITS PRIORITY ORIGINAL
ABBREVIATED
NEW DRUG APPLICATION FOR KETAMINE
Source text for Eikon: ID:nGNX2N771v
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application